Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A randomized phase II study of chemoradiation (CRT) plus /- nivolumab (Nivo) with sequential safety evaluations of Nivo plus /- lirilumab (Liri) or ipilumumab (Ipi) concomitant with (C) RI in intermediate (IR) and high-risk (HR) head and neck squamous cell carcinoma (HNSCC) (RTOG 3504, NCT02764593). Gillison, M. L., Ferris, R. L., Zhang, Q., Colevas, A., Mell, L. K., Kong, C., Jordan, R., Moore, K., Truong, M., Kirsch, C., Machtay, M., Curran, W., Le, Q. AMER SOC CLINICAL ONCOLOGY. 2017
View details for DOI 10.1200/JCO.2017.35.15_suppl.TPS6097
View details for Web of Science ID 000411931705093